参考文献:
1.Boger RH, Bode-Boger SM, Szuba A, Tangphao O, Tsao PS, Chan JR, Blaschke TF,Cooke JP. Asymmetric dimethylarginine: a novel risk factor for endothelialdysfunction.Its role in hypercholesterolemia.Circulation 1998;98: 1842-1847
2.Boger RH. The emerging role of asymmetric dimethylarginine as a novelcardiovascular risk factor.Cardiovasc Res. 2003;59: 824-833
3.Kielstein JT,Boger RH,Bode-Boger SM,et al. Asymmetric dimethylarginineplasma concentrations differ in patients with end-stage renal disease:Relationship to treatment method and atherosclerotic disease.JAm SocNephrol.1999; 10:594-600
4.Lu TM,Ding YA,Lin SJ,Lee WS,Tai HC. Plasma levels of asymmetricaldimethylarginine and adverse cardiovascular events after percutaneous coronaryintervention.Eur Heart J.2003;24: 1912-1919.
5.Nijveldt RJ,Teerlink T,Van der Hoven B, Siroen MP,Kuik DJ, Rauwerda JA, vanLeeuwen PA.Asymmetrical dimethylarginine in critically ill patients: highplasma Asymmetric dimethylarginine concentration is an independent risk factor of lCU mortality.ClinNutr. 2003;22: 23-30
6.Savvidou MD,Hingorani AD,Tsikas D, Frolich JC,Vallance P,Nicolaides KH.Endothelial dysfunction and raised plasma concentrations of asymmetricdimethylarginine in pregnant women who subsequently develop pre-eclampsia.Lancet 2003;361: 1511-1517
7.Stuhlinger M,Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, ReavenGM, Tsao PS.Relationship between insulin resistance and an endogenous nitricoxide synthase inhibitor.JAm Med Assoc. 2002;287:1420-1426
8.Vallance P,Leone A,Calver A,Collier J,Moncada S. Accumulation of anendogenous inhibitor of NO synthesis in chronic renal failure.Lancet 1992;339:572-575
9.Zoccali C, Bode-Boger SM,Mallamaci F, Benedetto FA,Tripepi G,Malatino L,Cataliotti A, Bellanuova l, Fermo l,Frolich JC, Boger RH. Asymmetric dimethylarginine: An endogenous inhibitor of nitric oxide synthasepredicts mortality in end-stage renal disease(ESRD).Lancet 2001;358:2113-2117
10.Aktoz T,Aktoz M, TatlnE,Kaplan M,Turan FN, Barutcu A, Atakan lH, Demir M,AltunA.Assessment of the Relationship between Asymmetric Dimethylarginine and Severity of Erectile Dysfunction and Coronary Artery Disease. Int Urol Nephrol.Dec; 42(4):873-9.doi: 10.1007/s11255-009-9696-9
11.Ayer JG, HarmerJA, Xuan W, Toelle B, Webb K, Almqvist C, Marks GB, Celermajer Ds.Dietary Supplementation with N-3 Polyunsaturated Fatty Acids in EarlyChildhood: Effects on Blood Pressure and Arterial Structure and Function at Age8 Y.Am JClin Nutr.2009 Aug; 90(2):438-46. doi: 10.3945/ajcn.2009.27811
12.Bang OY, Chung J, Kim SJ, Chung Jet al.Caveolin-1,Ring finger protein 213, and endothelial function in Moyamoya disease. Int J Stroke. 2016;0(0):1-10.doi:10.1177/1747493016662039
13.Brenner T, Fleming TH, Rosenhagen C Krauser U, Mieth M, Bruckner T, Martin E,Nawroth PP,Weigand MA,Bierhaus A, Hofer S. L-arginine and asymmetricdimethylarginine are early predictors for survival in septic patients with acuteliver failure.Mediators Inflamm. 2012:210454.doi:10.1155/2012/210454.
14.Celik M, Cerrah S, Arabul M Akalin A.Relation of asymmetric dimethylarginine levels to macrovascular disease and inflammation markers in type 2 diabeticpatients. J Diabetes Res.2014: 139215
15.KurtogluE, Balta S, Sincer l, Altas Y,Atas H, Yilmaz M, Korkmaz H, Erdem K,Akturk E, Demirkol S, Can C.Comparision of Effects of Rosuvastatin versus AtorvastatinTreatment on Plasma Levels of Asymmetric Dimethylarginine in Patients withHyperlipidemia Having Coronary Artery Disease.Angiology. 2014 65(9);:788-93.doi:10.1177/0003319713507333
16.Sandoo A, Dimitroulas T, Hodson J, Smith JP, Douglas KM, Kitas GD.Cumulative inflammation associates with asymmetric dimethylarginine in rheumatoidarthritis: a 6 year follow-up study. Rheumatology (Oxford, England).2014;(September 2014):1-8.doi:10.1093/rheumatology/keu349